News
Our latest news and announcements
Vaccine Development at CPI
The World’s population is facing increased threats of disease from pathogens. Whether it is an influenza pandemic or outbreak such as the recent Ebola crisis in Africa or diseases such as Malaria or Severe Acute Respiratory Syndrome (SARS), the need for cheaper, effective vaccines is on the rise. Thanks to advances in medicine, we can now use viruses to treat disease, and it’s this area of vaccine development where CPI can help.
CPI welcomes Katie Murray to Medicines Manufacturing Innovation Centre team
CPI are delighted to welcome Katie Murray to the Medicines Manufacturing Innovation Centre team. Katie will join CPI on a 2 year secondment from AstraZeneca as Technology Director of the centre starting in early 2020. Katie will be responsible for leading the development and delivery of the technology strategy, she will work closely with the team to enable the development of scientific knowledge and practice within the centre.
CPI partners with ImmunoBiology Ltd to manufacture heat-stabilised Pneumococcal vaccine formulation
CPI today announced a partnership with ImmunoBiology Ltd (ImmBio), Cambridge, to develop a heat-stabilised formulation for ImmBio’s multi-antigen vaccine candidate against Pneumococcal diseases. This will eliminate the requirement for a costly and complex cold chain, helping to reduce the cost of the vaccine and increase accessibility in LMICs (Low and Middle Income Countries) where cold chains may be lacking.